Eliminate, not recreate

TNF alpha inhibitors work well to suppress the inflammatory response in Crohn's disease, but only in one-third to one-half of patients. Enterome Bioscience S.A. is developing both a test to help physicians select the most appropriate drug for Crohn's disease patients, and a therapy for the indication that could be disease-modifying.

Enterome's diagnostic programs came out of research conducted by Stanislav Ehrlich and colleagues at INRA that identified problematic bacteria in the gut microbiome. Using meta-genomic sequence data from the microbiome of healthy volunteers and patients with inflammatory and other disorders, the researchers identified subgroups of bacterial species that play a functional role in obesity, inflammatory bowel disease (IBD) and Crohn's...